摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N,N'-bis(1,1,3,3-tetramethylbutyl)urea | 2092-58-2

中文名称
——
中文别名
——
英文名称
N,N'-bis(1,1,3,3-tetramethylbutyl)urea
英文别名
N,N'-di-tert-octylurea;N,N'-bis-(1,1,3,3-tetramethyl-butyl)-urea;N,N'-Bis-(1,1,3,3-tetramethyl-butyl)-harnstoff;N.N'-Bis-<1.1.3.3-tetramethyl-butyl>-harnstoff;1,3-Di-tert.-octyl-harnstoff;1,3-Bis(2,4,4-trimethylpentan-2-yl)urea
N,N'-bis(1,1,3,3-tetramethylbutyl)urea化学式
CAS
2092-58-2
化学式
C17H36N2O
mdl
——
分子量
284.486
InChiKey
BVBFFLTWVPZXRZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.8
  • 重原子数:
    20
  • 可旋转键数:
    6
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.94
  • 拓扑面积:
    41.1
  • 氢给体数:
    2
  • 氢受体数:
    1

SDS

SDS:d8439b67f96c31d29c71654f05bc0da4
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • The use of substituted carbocyclic compounds as rotamases inhibitors
    申请人:Jerini AG
    公开号:EP1402888A1
    公开(公告)日:2004-03-31
    The present invention is related to the use of a compound as an inhibitor to a rotamase, whereby the compound has the structure:         A-X-Y     (I) wherein A is cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl; X is a spacer and is selected from X1 or X2, wherein X1 is selected from the group comprising -[(CRaRb)n-NRc-CO-NRd-(CRaRb)m]t-, -[(CRaRb)n-NRc-CS-NRd-(CRaRb)m]t-, -[(CRaRb)n-NRc-C(N-CN)-NRd-(CRaRb)m]t-, -[(CRaRb)n-NRc-C(N-Re)-NRd-(CRaRb)m]t-, -[(CRaRb)n-CO-NRc-(CRaRb)m]t-, -[(CRaRb)n-NRc-(CRaRb)m]t-, -[(CRaRb)n-NRc-CO-O-(CRaRb)m]t-, -[(CRaRb)n-O-CO-NRc-(CRaRb)m]t-, -[(CRaRb)n-O-(CRaRb)m]t-, -[(CRaRb)n-SRc-(CRaRb)m]t-; wherein X2 is selected from the group comprising - [(CRaRb)n-CO-(CRaRb)m]t-, -[(CRaRb)n-CS-(CRaRb)m]t-, -[(CRaRb)n-NRc-CO-(CRaRb)m]t-, -[(CRaRb)n-CO-NRc-(CRaRb)m]t-, -[(CRaRb)n-NRc-CS-(CRaRb)m]t-, -[(CRaRb)n-CS-NRc-(CRaRb)m]t-, -[(CRaRb)n-NRc-SO2-(CRaRb)m]t-, -[(CRaRb)n-SO2-NRc-(CRaRb)m]t-, -[(CRaRb)n-SO-(CRaRb)m]t-, -[(CRaRb)n-SO2-(CRaRb)m]t-, -[(CRaRb)n]t-; wherein n and m are independently selected from each other and are any integer between 0 and 10 provided that if n is 0, m is different from 0, and if m is 0, n is different from 0; wherein t is independently selected from n and/or m and is any integer between 0 and 10; wherein Ra, Rb, Rc, Rd and Re are independently from each other selected from the group comprising H, alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; and wherein Y is selected from the group comprising alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heterocyclyl, substituted heterocyclyl, mono-unsaturated heterocyclyl, poly-unsaturated heterocyclyl, mono-substituted poly-unsaturated heterocyclyl, poly-substituted poly-unsaturated heterocyclyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl, wherein Y is different from a peptide.
    本发明涉及将某种化合物作为旋转酶的抑制剂使用,其中该化合物具有以下结构:        A-X-Y     (I)其中A为环烷基、取代环烷基、杂环烷基、取代杂环烷基、芳基、取代芳基、杂芳基或取代杂芳基;X为间隔物,可从X1或X2中选择,其中X1可从以下组中选择:-[(CRaRb)n-NRc-CO-NRd-(CRaRb)m]t-,-[(CRaRb)n-NRc-CS-NRd-(CRaRb)m]t-,-[(CRaRb)n-NRc-C(N-CN)-NRd-(CRaRb)m]t-,-[(CRaRb)n-NRc-C(N-Re)-NRd-(CRaRb)m]t-,-[(CRaRb)n-CO-NRc-(CRaRb)m]t-,-[(CRaRb)n-NRc-(CRaRb)m]t-,-[(CRaRb)n-NRc-CO-O-(CRaRb)m]t-,-[(CRaRb)n-O-CO-NRc-(CRaRb)m]t-,-[(CRaRb)n-O-(CRaRb)m]t-,-[(CRaRb)n-SRc-(CRaRb)m]t-;其中X2可从以下组中选择:-[(CRaRb)n-CO-(CRaRb)m]t-,-[(CRaRb)n-CS-(CRaRb)m]t-,-[(CRaRb)n-NRc-CO-(CRaRb)m]t-,-[(CRaRb)n-CO-NRc-(CRaRb)m]t-,-[(CRaRb)n-NRc-CS-(CRaRb)m]t-,-[(CRaRb)n-CS-NRc-(CRaRb)m]t-,-[(CRaRb)n-NRc-SO2-(CRaRb)m]t-,-[(CRaRb)n-SO2-NRc-(CRaRb)m]t-,-[(CRaRb)n-SO-(CRaRb)m]t-,-[(CRaRb)n-SO2-(CRaRb)m]t-,-[(CRaRb)n]t-;其中n和m相互独立选择,为0到10之间的任意整数,条件是如果n为0,则m与0不同,如果m为0,则n与0不同;其中t从n和/或m中独立选择,为0到10之间的任意整数;其中Ra、Rb、Rc、Rd和Re相互独立选择,可从H、烷基、环烷基、芳基、杂芳基和杂环烷基中选择;Y可从烷基、取代烷基、环烷基、取代环烷基、环烯基、取代环烯基、杂环烷基、取代杂环烷基、单不饱和杂环烷基、多不饱和杂环烷基、单取代多不饱和杂环烷基、多取代多不饱和杂环烷基、芳基、取代芳基、杂芳基和取代杂芳基中选择,其中Y与肽不同。
  • New compounds for the inhibition of undesired cell proliferation and use thereof
    申请人:Jerini AG
    公开号:EP1402887A1
    公开(公告)日:2004-03-31
    The present invention is related to the use of a compound for the manufacture of a medicament for the treatment of a disease, whereby the disease involves an abnormal cell proliferation, an undesired cell proliferation, an abnormal mitosis and/or an undesired mitosis. whereby the compound has the structure:         A-X-Y     (I) wherein A is cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl; X is a spacer and is selected from X1 or X2, wherein X1 is selected from the group comprising -[(CRaRb)n-NRc-CO-NRd-(CRaRb)m]t-, [(CRaRb)n-NRc-CS-NRd-(CRaRb)m]t-, -[(CRaRb)n-NRc-C(N-CN)-NRd-(CRaRb)m]t-, -[(CRaRb)n-NRc-C(N-Re)-NRd-(CRaRb)m]t-, -[(CRaRb)n-CO-NRc-(CRaRb)m]t-, -[(CRaRb)n-NRc-(CRaRb)m]t-, -[(CRaRb)n-NRc-CO-O-(CRaRb)m]t-, -[(CRaRb)n-O-CO-NRc-(CRaRb)m]t-, -[(CRaRb)n-O-(CRaRb)m]t-, -[(CRaRb)n-SRc-(CRaRb)m]t-; wherein X2 is selected from the group comprising -[(CRaRb)n-CO-(CRaRb)m]t-, -[(CRaRb)n-CS-(CRaRb)m]t-, -[(CRaRb)n-NRc-CO-(CRaRb)m]t-, -[(CRaRb)n-CO-NRc-(CRaRb)m]t-, -[(CRaRb)n-NRc-CS-(CRaRb)m]t-, -[(CRaRb)n-CS-NRc-(CRaRb)m]t-, -[(CRaRb)n-NRc-SO2-(CRaRb)m]t-, -[(CRaRb)n-SO2-NRc-(CRaRb)m]t-, -[(CRaRb)n-SO-(CRaRb)m]t-, -[(CRaRb)n-SO2-(CRaRb)m]t-, -[(CRaRb)n]t-; wherein n and m are independently selected from each other and are any integer between 0 and 10 provided that if n is 0, m is different from 0, and if m is 0, n is different from 0; wherein t is independently selected from n and/or m and is any integer between 0 and 10; wherein Ra, Rb, Rc, Rd and Re are independently from each other selected from the group comprising H, alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; and wherein Y is selected from the group comprising alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heterocyclyl, substituted heterocyclyl, mono-unsaturated heterocyclyl, poly-unsaturated heterocyclyl, mono-substituted poly-unsaturated heterocyclyl, poly-substituted poly-unsaturated heterocyclyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl, wherein Y is different from a peptide.
    本发明涉及一种化合物用于制造治疗疾病的药物,其中该疾病涉及异常细胞增殖、不良细胞增殖、异常有丝分裂和/或不良有丝分裂,其中该化合物具有以下结构:A-X-Y(I),其中A为环烷基、取代环烷基、杂环烷基、取代杂环烷基、芳香族、取代芳香族、杂芳香族或取代杂芳香族;X为间隔物,选择自X1或X2,其中X1选择自包括-[(CRaRb)n-NRc-CO-NRd-(CRaRb)m]t-、[(CRaRb)n-NRc-CS-NRd-(CRaRb)m]t-、-[(CRaRb)n-NRc-C(N-CN)-NRd-(CRaRb)m]t-、-[(CRaRb)n-NRc-C(N-Re)-NRd-(CRaRb)m]t-、-[(CRaRb)n-CO-NRc-(CRaRb)m]t-、-[(CRaRb)n-NRc-(CRaRb)m]t-、-[(CRaRb)n-NRc-CO-O-(CRaRb)m]t-、-[(CRaRb)n-O-CO-NRc-(CRaRb)m]t-、-[(CRaRb)n-O-(CRaRb)m]t-、-[(CRaRb)n-SRc-(CRaRb)m]t-;其中X2选择自包括-[(CRaRb)n-CO-(CRaRb)m]t-、-[(CRaRb)n-CS-(CRaRb)m]t-、-[(CRaRb)n-NRc-CO-(CRaRb)m]t-、-[(CRaRb)n-CO-NRc-(CRaRb)m]t-、-[(CRaRb)n-NRc-CS-(CRaRb)m]t-、-[(CRaRb)n-CS-NRc-(CRaRb)m]t-、-[(CRaRb)n-NRc-SO2-(CRaRb)m]t-、-[(CRaRb)n-SO2-NRc-(CRaRb)m]t-、-[(CRaRb)n-SO-(CRaRb)m]t-、-[(CRaRb)n-SO2-(CRaRb)m]t-、-[(CRaRb)n]t-;其中n和m彼此独立选择且为0和10之间的任意整数,条件是如果n为0,则m不等于0,如果m为0,则n不等于0;其中t独立选择自n和/或m,为0和10之间的任意整数;其中Ra、Rb、Rc、Rd和Re独立于彼此选择自包括H、烷基、环烷基、芳香族、杂芳香族和杂环烷基;Y选择自包括烷基、取代烷基、环烷基、取代环烷基、环烷烯基、取代环烷烯基、杂环烷基、取代杂环烷基、单不饱和杂环烷基、多不饱和杂环烷基、单取代多不饱和杂环烷基、多取代多不饱和杂环烷基、芳香族、取代芳香族、杂芳香族和取代杂芳香族,其中Y与肽不同。
  • Solvent-Free Synthesis of Urea Derivatives from Primary Amines and Sulfur under Carbon Monoxide and Oxygen at Atmospheric Pressure
    作者:Takumi Mizuno、Masatoshi Mihara、Takeo Nakai、Toshiyuki Iwai、Takatoshi Ito
    DOI:10.1055/s-2007-990793
    日期:2007.10
    was developed. With these reactions, an environmentally benign synthesis of urea derivatives could be carried out in good to excellent yields from primary amines and sulfur at ambient pressure of carbon monoxide and oxy-gen. For example, N, N′-dioctylurea was prepared in 99% yield from two equivalents octylamine and one equivalent sulfur in the presence of carbon monoxide (1 atm) at 80 °C and oxygen
    开发了一种针对绿色和可持续化学的无溶剂羰基化和氧化系统。通过这些反应,可以在一氧化碳和氧气的环境压力下以良好至优异的产率从伯胺和硫进行环境友好的尿素衍生物合成。例如,在 80 °C 的一氧化碳 (1 atm) 和室温下的氧气 (1 atm) 存在下,由两个当量的辛胺和一个当量的硫以 99% 的收率制备 N,N'-二辛基脲,完全没有溶剂。
  • Isocyanates — Part 3.7 Synthesis of carbamates by DMAP-catalyzed reaction of amines with di-tert-butyldicarbonate and alcohols
    作者:Hans-Joachim Knölker、Tobias Braxmeier
    DOI:10.1016/0040-4039(96)01248-8
    日期:1996.8
    Carbamates are prepared by DMAP-catalyzed reaction of amines with di-tert-butyldicarbonate and subsequent trapping of the intermediate isocyanates with alcohols.
    氨基甲酸酯是通过DMAP催化胺与碳酸二叔丁酯的反应,然后用醇捕获中间异氰酸酯而制得的。
  • Preparation of ureas
    申请人:MONSANTO CHEMICALS
    公开号:US02857430A1
    公开(公告)日:1958-10-21
查看更多